New generation of dendritic cell vaccines

Kristen J Radford, Irina Caminschi

Research output: Contribution to journalReview ArticleOtherpeer-review

24 Citations (Scopus)

Abstract

Dendritic cells (DC) play a pivotal role in the induction and regulation of immune responses, including the induction of cytotoxic T lymphocytes (CTL) responses. These are essential for the eradication of cancers and pathogens including HIV and malaria, for which there are currently no effective vaccines. New developments in our understanding of DC biology have identified the key DC subset responsible for CTL induction, which is now an attractive candidate to target for vaccination. These DC are characterized by expression of novel markers Clec9A and XCR1, and a specialized capacity to cross-present antigen (Ag) from tumors and pathogens that do not directly infect DC. New generation DC vaccines that specifically target the cross-presenting DC in vivo have already demonstrated potential in preclinical animal models but the challenge remains to translate these findings into clinically efficacous vaccines in man. This has been greatly facilitated by the recent identification of the equivalent Clec9A+XCR1+ cross-presenting DC in human lymphoid tissues and peripheral tissues that are key sites for vaccination administration. These findings combined with further studies on DC subset biology have important implications for the design of new CTL-mediated vaccines.

Original languageEnglish
Pages (from-to)259-264
Number of pages6
JournalHuman Vaccines & Immunotherapeutics
Volume9
Issue number2
DOIs
Publication statusPublished - 2013
Externally publishedYes

Keywords

  • Cytotoxic T cells
  • Dendritic cells
  • Targeting
  • Tumor immunity
  • Vaccines

Cite this